Coronary intervention and glycoprotein IIb/IIIa integrin blockade

Coronary Artery Disease

Volumn 10, Issue 8, 1999, Pages 553-560

  Madan, Mina ^a   Tcheng, James E ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Coronary intervention; Glycoprotein IIb IIIa; Platelet aggregation inhibitors

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW;

EID: 0032761627     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199912000-00003     Document Type: Review

References (33)

1. 1 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332:1553-1559.
2. 2 Phillips DR, Charo IF, Scarborough RM. GP IIb-IIIa: the responsive integrin. Cell 1991; 65:359-362.
3. 3 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72:325-338.
4. 4 Crenshaw BS, Harrington RA, Tcheng JE. Novel antiplatelet agents: the glycoprotein IIb/IIIa inhibitors. Exp Opin Invest Drugs 1995; 4:1033-1044.
5. 5 Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97:1680-1688.
6. 6 EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-961. Thirty-day ischemic complications of high-risk coronary interventions were reduced by 35% using abciximab (bolus + infusion) treatment; however, the risk of bleeding was increased. This landmark study inaugurated the era of glycoprotein IIb/IIIa inhibition in cardiovascular medicine, by validating the hypothesis that blockade of the platelet glycoprotein IIb/IIIa receptor would improve clinical outcomes.
7. 7 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336:1689-1696. In both high-risk and low-risk patients undergoing angioplasty, glycoprotein IIb/IIIa blockade with abciximab and low-dose weight-adjusted heparin markedly reduced the incidence of ischemic complications at 30 days, without increasing the risk of bleeding events. This study led to an improved safety profile for glycoprotein IIb/IIIa antagonists by introducing several new concepts: reduction and weight-adjustment of heparin dosing when glycoprotein IIb/IIIa inhibitors are used; careful monitoring of the activated clotting time (aiming for 200-300 s); early vascular sheath removal at 4-6 h after the procedure, while abciximab is infusing.
8. 8 The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349:1429-1435.
9. 9 The EPISTENT Investigators. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotoin IIb/IIIa blockade. Lancet 1998; 352:87-92.
10. 10 The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997; 349:1422-1428.
11. 11 The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96:1445-1453.
12. 12 Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. The Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication (EPIC) Investigator Group. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA 1997; 278:479-484. At 3-year follow-up in the EPIC trial, the combined incidence of death, myocardial infarction or coronary revascularization was reduced in patients initially treated with abciximab (bolus + infusion) relative to placebo-treated controls (41.1% compared with 47.2%, P= 0.009). Although this study showed a durable treatment effect for abciximab up to 3 years after treatment, these results have not been replicated in other trials of abciximab, or with other glycoprotein IIb/IIIa inhibitors.
13. 13 Adgey JAA. Overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J 1998; 135 (suppl): S43-S55. An excellent and up-to-date overview of alt trials of glycoprotein IIb/IIIa inhibition.
14. 14 Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90:1757-1764.
15. 15 Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff MA, Tcheng JE, Sigmon KN, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76:1222-1227.
16. 2+ from the platelet glycoprotein IIb/IIIa receptors and enhances the apparent inhibitory activity of eptifibatide. This study suggested that it may be possible to achieve greater efficacy with higher doses of eptifibatide, beyond that observed in earlier clinical trials such as IMPACT II.
17. 17 Ferguson JJ. Meeting highlights: XIX Congress of the European Society of Cardiology. Circulation 1997; 96:3818-3821.
18. 18 Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996; 78:1161-1163.
19. 19 Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997; 95:809-813. One of the first reports characterizing the entity of acute profound thrombocytopenia; it includes a comprehensive algorithm for diagnosis and management of this condition.
20. 20 Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997; 96:3809.
21. 21 Bednar B, Bednar RA, Cook JJ, Bollag DM, Chang CT, Stanley LG, et al. Drug-dependent antibodies against GP IIb/IIIa induce thrombocytopenia [abstract]. Circulation 1996; 94:1-99.
22. 22 Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al., on behalf of The EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343:881-886.
23. 23 Ellis SG, Serruys PW, Popma JJ, Teirstein PS, Ricci DR, Gold HK, et al. Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results [abstract]. Circulation 1997; 96:1-87.
24. 24 Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. W Engl J Med 1994; 331:489-495.
25. 25 Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496-501.
26. 26 Braden GA, Applegate RJ, Young TM, Love WW, Sane DC. Abciximab decreases both the incidence and magnitude of creatinine kinase elevation during rotational atherectomy [abstract]. J Am Coll Cardiol 1997; 29:499A.
27. 27 Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley JD, Worley SJ, et al. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. J Am Coll Cardiol 1996; 28:849-855.
28. 28 Grines CL, Browne KR, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of primary angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328:673-679.
29. 29 Stone GW. Stenting in acute myocardial infarction: observational studies and randomized trials - 1998. J Invas Cardiol 1998; 10 (suppl A):16A-26A.
30. 30 Tcheng JE. Platelet integrin glycoprotein IIb/IIIa inhibitors: opportunities and challenges. J Invas Cardiol 1996; 8 (suppl B):8B-14B.
31. 31 Gold HK, Garbedian HD, Dinsmore RE, Guerrero U, Cigarroa JE, Palacios IF, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation 1997; 95:1755-1759. One of the first reports to document improvement in arterial patency after treatment of patients with acute myocardial infarction with abciximab alone (without thrombolytic therapy). These observations provided the impetus for the current intense investigation of glycoprotein IIb/IIIa inhibition in the setting of acute myocardial infarction.
32. 32 Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC Investigators. Am J Cardiol 1996; 77:1045-1051.
33. 33 Brener SJ, Barr LA, Burchenal J, Katz S, George BS, Jones AA, et al. A randomized, placebo-controlled trial of abciximab with primary angioplasty for acute MI. The RAPPORT trial [abstract]. Circulation 1997; 96:1-473.